Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial

ConclusionsAbrocitinib provided rapid and substantially greater improvements in skin clearance and quality of life compared with placebo and dupilumab in subgroups of patients with severe and/or difficult-to-treat AD. These findings support the use of abrocitinib for severe and/or difficult-to-treat AD.Trial registration:ClinicalTrials.gov, NCT03720470.

http://link.springer.com/10.1007/s40257-023-00785-5

Source: American Journal of Clinical Dermatology - May 22, 2023 Category: Dermatology Source Type: research